|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For each histopathologic diagnosis, the number of cases and positive rate of c-Met expression are as follows: oligodendroglioma, IDH-mutant, and 1p19q codeletion (OD): 16 cases, 6.3%; anaplastic oligodendroglioma, IDH-mutant, and 1p19q codeletion (AO): 11 cases, 36.4%; diffuse astrocytoma (DA), IDH-mutant: 21 cases, 28.6%; anaplastic astrocytoma (AA), IDH- mutant: 15 cases, 20%; glioblastoma, IDH-mutant: 2, 100%, DA, IDH-wildtype: 9 cases, 33.3%; AA, IDH-wildtype: 20 cases, 30.0%; and glioblastoma, IDH-wildtype: 59 cases, 52.5%. c-Met expression was correlated with progression-free survival in oligodendroglial tumors and glioblastoma, IDH-wildtype.
|
30878754 |
2019 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
According to the 2016 World Health Organization Classification of Tumors of the Central Nervous System (2016 CNS WHO), IDH-mutant astrocytic gliomas comprised WHO grade II diffuse astrocytoma, IDH-mutant (AII<sub>IDHmut</sub>), WHO grade III anaplastic astrocytoma, IDH-mutant (AAIII<sub>IDHmut</sub>), and WHO grade IV glioblastoma, IDH-mutant (GBM<sub>IDHmut</sub>).
|
29687258 |
2018 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with IDH mutant glioblastoma had a distinctly higher survival profile than both rs11554137:C>T SNP and IDH wild type glioblastomas.
|
29423539 |
2018 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These groups are: (1) Oligodendroglioma, IDH-mutant and 1p/19q-codeleted; (2) Astrocytoma, IDH-mutant; (3) Glioblastoma, IDH-mutant; (4) Glioblastoma, IDH-wildtype; and (5) Astrocytoma, IDH-wildtype.
|
28255664 |
2017 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oncogenic mutations in two isocitrate dehydrogenase (IDH)-encoding genes (IDH1 and IDH2) have been identified in acute myelogenous leukemia, low-grade glioma, and secondary glioblastoma (GBM).
|
28564604 |
2017 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Isocitrate dehydrogenase (IDH1/IDH2) mutations in gliomas of WHO grade II/III and secondary glioblastoma are almost always heterozygous missense mutations.
|
28782849 |
2017 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
Biomarker
|
disease |
BEFREE |
The recent 2016 WHO classification for CNS tumors categorizes diffuse glioma into two major types that include IDH wild-type glioblastoma, which is the predominant type and IDH-mutant glioblastoma, which is less common and displays better prognosis.
|
28730141 |
2017 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
One such difference concerns mutations in the NADP(+)-dependent isocitrate dehydrogenase (IDH1 and IDH2) genes, which occur in >80% of cases of low grade glioma and secondary glioblastoma.
|
24747768 |
2014 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IDH mutation appears to be a significant marker of positive chemosensitivity in secondary glioblastoma.
|
22034964 |
2012 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Some findings, such as that of IDH mutation in low-grade gliomas and secondary glioblastoma (GBM), fit well into established notions of different routes of gliomagenesis.
|
21465149 |
2011 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
New and unexpected discoveries have also been made, such as frequent mutations of the IDH1 and IDH2 genes in secondary glioblastoma.
|
19597514 |
2009 |